newsfilter
← Latest News
Business Wire·

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURA
  • Zura Bio Limited priced an underwritten public offering of 18,200,000 Class A ordinary shares at $6.25 per share.
  • Investors could elect to receive pre-funded warrants for 1,800,000 shares at $6.249 per warrant instead of Class A ordinary shares.
  • Zura granted underwriters a 30-day option to purchase up to 3,000,000 additional Class A ordinary shares.
  • The offering is expected to generate gross proceeds of $125 million before deducting underwriting discounts, commissions, & other expenses.
  • The transaction is scheduled to close on February 26, 2026, subject to customary closing conditions.
  • Leerink Partners, Piper Sandler, & Cantor are acting as joint bookrunning managers, with Wedbush PacGrow serving as the lead manager.
  • The securities are being offered pursuant to an effective Form S-3 shelf registration statement filed with the SEC on September 17, 2024.
  • Zura is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
  • The company's lead candidate tibulizumab (ZB-106) is currently in two Phase 2 studies for hidradenitis suppurativa & systemic sclerosis.
  • Additional candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are under evaluation.